hrp0097s6.3 | Neonatal endocrinology | ESPE2023

The developing HPA axis: establishing diurnal variation in cortisol secretion

Finken Martijn

In adults and older children with adrenal insufficiency, hydrocortisone replacement therapy is based on the assumption that the secretion of cortisol follows a diurnal pattern, with a peak in the early morning, a gradual decline over the day and a nadir at midnight. However, replacement therapy with multiple daily doses of hydrocortisone is unable to exactly match the normal diurnal rhythm of cortisol secretion from an intact hypothalamus-pituitary-adrenal (HPA) axis, with con...

hrp0092p2-53 | Bone, Growth Plate and Mineral Metabolism | ESPE2019

Idiopathic Infantile Hypercalcemia: Mutations in SLC34A1 and CYP24A1 in Two Siblings and Fathers

Güven Ayla , Konrad Martin , Schlingmann Karl Peter

Background: Both CYP24A1 and SLC34A1 gene mutations are responsible for idiopathic infantile hypercalcemia (IIH). Whereas loss-of-function mutations in CYP24A1 (25-OH-vitamin D-24-hydroxylase) lead to a defect in the inactivation of active 1,25(OH)2-vitamin D3, mutations in SLC34A1 encoding renal sodium-phosphate co-transporter NaPi-IIa lead to primary renal phosphate wasting combined with an inappropri...

hrp0092p2-74 | Diabetes and Insulin | ESPE2019

Impact of the Flash Glucose Monitoring System on Children with Type 1 Diabetes After the First Year of Using in Systematic Way

Freijo Martin Concepcion , Bertholt Zuber Laura , Palenzuela Inmaculada

The Flash glucose monitoring System(FGMS) is a system of measurement of the interstitial glucose levels in real time, safe, effective and doesn´t require calibration. Its low cost has allowed to be approved for all children under 18 years old by our Regional Health Service.Objective: To assess the impact during this first year of use of FGMS in all children diagnosed with type 1 diabetes who previously used the classic method of cap...

hrp0089p1-p125 | Fat, Metabolism and Obesity P1 | ESPE2018

M2 Macrophage Markers are Enriched in Human Deep Neck Adipose Tissue and Do Not Correlate with UCP1 Expression

Tews Daniel , Haggenmueller Benedikt , Wabitsch Martin , Fischer-Posovszky Pamela

Background: Secretion of catecholamines by adipose tissue M2 macrophages was recently proposed as a molecular mechanism leading to activation of brown adipose tissue and heat generation in mice. However, published data are conflicting and it is not clear whether this pathway might play a role in humans. To shed light on this, we studied macrophage polarization in human white and brown adipose tissue and related it to thermogenic gene expression.Methods: ...

hrp0089p3-p228 | Growth & Syndromes P3 | ESPE2018

Children Born Small for Gestational Age: Catch-up Growth During the First Four Years of Life

Freijo Martin Concepcion , Bertholt Zuber Laura , Palenzuela Revuelta Inmaculada

Children born small for gestational age (SGA) have a weight and/or heighth less than −2SD from the mean, the realization of an adequate catch-up or not during the first years is important and the growth assessment is required.Objective: Analyze Catch-up on Growth of 52 SGA children during the first 4 years of life, compared 23 children who performed it properly (AC) with 19 who did not recover (NAC).Methods: Retrospective stu...

hrp0086fc8.2 | Growth: Clinical | ESPE2016

Whole Exome Sequencing can Identify Defects not Detected by Candidate Gene Sequencing in Patients with Short Stature and Features of Growth Hormone Insensitivity (GHI)

Shapiro Lucy , Savage Martin , Davies Kate , Metherell Lou , Storr Helen

Background: GH insensitivity (GHI) encompasses growth failure, low serum IGF-1 and normal/elevated serum growth hormone (GH) (basal level >5 μg/L and/or peak on provocation testing >10 μg/L). In a significant number of children the molecular cause is unknown.Objective: To investigate the genetic etiology of GHI in a cohort of children by candidate gene (CGS) and whole exome (WES) sequencing.Methods: About 109 pati...

hrp0086p1-p695 | Endocrinology and Multisystemic Diseases P1 | ESPE2016

CANDLE Syndrome: A New Autoinflammatory Lipodystrophic Disorder with Challenging Diagnosis and Limited Therapeutic Options

Boyadzhiev Martin , Boyadzhiev Veselin , Marinov Luchezar , Iotova Violeta

Background: We present a 3 years old boy born on term from young non-consanguineous parents with negative family history. Shortly after birth swelling of the feet and multiple generalised erythematous cutaneous plaques and nodules gradually appeared. Recurrent fever attacks, hepatosplenomegaly, significant growth delay (height – 4.0 S.D.) and progressive loss of subcutaneus fat tissue followed.Objective and hypotheses: Laboratory inve...

hrp0086p1-p815 | Syndromes: Mechanisms and Management P1 | ESPE2016

6-Year-Old Girl with Mutation in DNMT3A – A New Overgrowth Syndrome

Ronholt Ann-Margrethe , Boxil Martin , Jensen Uffe , Hertz Birgitte

Background: Overgrowth disorders are a heterogeneous group of conditions characterized by increased growth and other clinical features. Overgrowth may be apparent at birth and can be static or progressive. Some syndromes are associated with increased tumor risk.Objective and hypotheses: A 6-year-old girl with accelerated growth rate was referred. She was born at term and was 55 cm long at birth (+2.4 SD). At 6 years, she was 134.4 cm tall (+3.7 SD) with ...

hrp0082p1-d3-134 | Fat Metabolism & Obesity (2) | ESPE2014

Can Hypothalamic Obesity be Treated with Stimulants?

Denzer Friederike , Lennerz Belinda , Denzer Christian , Wabitsch Martin

Background: Published case reports and anecdotal experience suggest a positive effect of dexamphetamine on impetus and weight in patients with hypothalamic obesity.Objective and hypotheses: We aimed to observe these effects in our patients who are offered off-label treatment with dexamphetamine.Method: Between 2010 and 2013, patients starting dexamphetamine treatment were enrolled in a prospective observation study. BMI–SDS wa...

hrp0082p2-d2-599 | Thyroid (1) | ESPE2014

Severe Urticaria in Graves’ Disease: is Carbimazole to Blame?

Ponmani Caroline , Mcclatchey Martin , Kanzaria Shilpa , Keane Morgan , Banerjee Kausik

Background: Carbimazole is widely used in the treatment of Graves’ disease and is well tolerated but can produce adverse effects in 5% of cases. Urticaria, which can develop as a drug reaction to carbimazole responds to withdrawal of the drug and symptomatic management. Urticaria is also a rare manifestation of thyrotoxicosis and does not respond to treatment, but regresses rapidly with the control of underlying hyperthyroidism.Objective and hypothe...